Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model

Nutrients. 2022 Jul 25;14(15):3044. doi: 10.3390/nu14153044.

Abstract

3,5-Diiodothyronine (3,5-T2) has been shown to exert pleiotropic beneficial effects. In this study we investigated whether 3,5-T2 prevent several energy metabolism disorders related to type 2 diabetes mellitus (T2DM) in gerbils diabetes-prone P. obesus. 157 male gerbils were randomly to Natural Diet (ND-controlled) or a HED (High-Energy Diet) divided in: HED- controlled, HED-3,5-T2 and HED- Placebo groups. 3,5-T2 has been tested at 25 µg dose and was administered under subcutaneous pellet implant during 10 weeks. Isolated hepatocytes were shortly incubated with 3,5-T2 at 10-6 M and 10-9 M dose in the presence energetic substrates. 3,5-T2 treatment reduce visceral adipose tissue, prevent the insulin resistance, attenuated hyperglycemia, dyslipidemia, and reversed liver steatosis in diabetes P. obesus. 3,5-T2 decreased gluconeogenesis, increased ketogenesis and enhanced respiration capacity. 3,5-T2 potentiates redox and phosphate potential both in cytosol and mitochondrial compartment. The use of 3,5-T2 as a natural therapeutic means to regulate cellular energy metabolism. We suggest that 3,5-T2 may help improve the deleterious course of obesity and T2DM, but cannot replace medical treatment.

Keywords: 3,5-Diiodothyronine (3,5-T2); Psammomys obesus; basal metabolic rate; gluconeogenesis; isolated hepatocytes; ketogenesis; obesity; oxygen consumption; type 2 diabetes.

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / metabolism
  • Diiodothyronines
  • Disease Models, Animal
  • Gerbillinae
  • Insulin / therapeutic use
  • Male
  • Obesity / drug therapy
  • Obesity / metabolism
  • Thyroid Hormones

Substances

  • Diiodothyronines
  • Insulin
  • Thyroid Hormones
  • 3,5-diiodothyronine

Grants and funding

The authors would like to acknowledge the financial support of the Algerian Agency for the Research & Development in Health (PNR No. 208/ANDRS and PNR No.41/ANDRS/2011) and the Algerian Ministry of Higher Education Program (No. D00L01UN160420200001).